Design Therapeutics, Inc. (DSGN)
After hours:
| Previous close | 4.6900 |
| Open | 4.6500 |
| Bid | 4.6600 x 300 |
| Ask | 4.7100 x 500 |
| Day's range | 4.5000 - 5.2300 |
| 52-week range | 1.9400 - 8.3100 |
| Volume | |
| Avg. volume | 311,380 |
| Market cap | 264.962M |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1900 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.67 |
GlobeNewswireDesign Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTACTM Pipeline Programs in Huntington’s Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-of-Concept CARLS
- GlobeNewswire
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The
Simply Wall St.Independent Director of Design Therapeutics Picks Up 88% More Stock
Whilst it may not be a huge deal, we thought it was good to see that the Design Therapeutics, Inc. ( NASDAQ:DSGN...
